Literature DB >> 30417892

In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells.

Raïko Blondonnet1, Bertille Paquette2, Damien Richard3, Rémi Bourg4, Géraldine Laplace4, Romain Segurel4, Henria Pouvelle4, Corinne Belville5, Loic Blanchon5, Thomas Godet2, Jean-Michel Constantin2, Jean-Etienne Bazin2, Vincent Sapin5, Matthieu Jabaudon2.   

Abstract

Acute respiratory distress syndrome (ARDS) is a syndrome of diffuse alveolar injury with impaired alveolar fluid clearance and severe inflammation. The use of halogenated agents, such as sevoflurane or isoflurane, for the sedation of intensive care unit (ICU) patients can improve gas exchange, reduce alveolar edema, and attenuate inflammation during ARDS. However, data on the use of inhaled agents for continuous sedation in the ICU to treat or prevent lung damage is lacking. To study the effects of halogenated agents on alveolar epithelial cells under "physiologic" conditions, we describe an easy system to culture cells at the air-liquid interface and expose them to halogenated agents to provide precise controlled "air" fractions and "medium" concentrations for these agents. We developed a sealed air-tight chamber in which plates with human alveolar epithelial immortalized cells could be exposed to a precise, controlled fraction of sevoflurane or isoflurane using a continuous gas flow provided by an anesthetic machine circuit. Cells were exposed to 4% of sevoflurane and 1% of isoflurane for 24 hours. Gas mass spectrometry was performed to determine the concentration of halogenated agents dissolved in the medium. After the first hour, the concentrations of sevoflurane and isoflurane in the medium were 251 mg/L and 25 mg/L, respectively. The curves representing the concentrations of both sevoflurane and isoflurane dissolved in the medium showed similar courses over time, with a plateau reached at one hour after exposure. This protocol was specifically designed to reach precise and controlled concentrations of sevoflurane or isoflurane in vitro to improve our understanding of mechanisms involved in epithelial lung injury during ARDS and to test novel therapies for the syndrome.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30417892      PMCID: PMC6235595          DOI: 10.3791/58554

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

1.  Anesthetic-induced improvement of the inflammatory response to one-lung ventilation.

Authors:  Elisena De Conno; Marc P Steurer; Moritz Wittlinger; Marco P Zalunardo; Walter Weder; Didier Schneiter; Ralph C Schimmer; Richard Klaghofer; Thomas A Neff; Edith R Schmid; Donat R Spahn; Birgit Roth Z'graggen; Martin Urner; Beatrice Beck-Schimmer
Journal:  Anesthesiology       Date:  2009-06       Impact factor: 7.892

2.  Soluble Receptor for Advanced Glycation End-Products Predicts Impaired Alveolar Fluid Clearance in Acute Respiratory Distress Syndrome.

Authors:  Matthieu Jabaudon; Raiko Blondonnet; Laurence Roszyk; Damien Bouvier; Jules Audard; Gael Clairefond; Mathilde Fournier; Geoffroy Marceau; Pierre Déchelotte; Bruno Pereira; Vincent Sapin; Jean-Michel Constantin
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

3.  An estimation of the global volume of surgery: a modelling strategy based on available data.

Authors:  Thomas G Weiser; Scott E Regenbogen; Katherine D Thompson; Alex B Haynes; Stuart R Lipsitz; William R Berry; Atul A Gawande
Journal:  Lancet       Date:  2008-06-24       Impact factor: 79.321

Review 4.  Acute Respiratory Distress Syndrome.

Authors:  B Taylor Thompson; Rachel C Chambers; Kathleen D Liu
Journal:  N Engl J Med       Date:  2017-08-10       Impact factor: 91.245

5.  Isoflurane Ameliorates Acute Lung Injury by Preserving Epithelial Tight Junction Integrity.

Authors:  Joshua A Englert; Alvaro A Macias; Diana Amador-Munoz; Miguel Pinilla Vera; Colleen Isabelle; Jiazhen Guan; Brady Magaoay; Margarita Suarez Velandia; Anna Coronata; Awapuhi Lee; Laura E Fredenburgh; Deborah J Culley; Gregory Crosby; Rebecca M Baron
Journal:  Anesthesiology       Date:  2015-08       Impact factor: 7.892

6.  Sevoflurane reduces severity of acute lung injury possibly by impairing formation of alveolar oedema.

Authors:  M Schläpfer; A C Leutert; S Voigtsberger; R A Lachmann; C Booy; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

7.  Determinants of long-term survival after major surgery and the adverse effect of postoperative complications.

Authors:  Shukri F Khuri; William G Henderson; Ralph G DePalma; Cecilia Mosca; Nancy A Healey; Dharam J Kumbhani
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

8.  Sevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injury.

Authors:  Stefanie Voigtsberger; Robert A Lachmann; Anik C Leutert; Martin Schläpfer; Christa Booy; Livia Reyes; Martin Urner; Julia Schild; Ralph C Schimmer; Beatrice Beck-Schimmer
Journal:  Anesthesiology       Date:  2009-12       Impact factor: 7.892

9.  Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man.

Authors:  R W D Nickalls; W W Mapleson
Journal:  Br J Anaesth       Date:  2003-08       Impact factor: 9.166

10.  Isoflurane preconditioning ameliorates endotoxin-induced acute lung injury and mortality in rats.

Authors:  Qi Fang Li; Ye Sen Zhu; Hong Jiang; Hui Xu; Yu Sun
Journal:  Anesth Analg       Date:  2009-11       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.